So we saw updates from DESTINY-Breast03 at San Antonio here in 2022. This trial had previously reported a significant improvement in progression-free survival with trastuzumab deruxtecan, compared to the previous second-line therapy for HER2-positive metastatic breast cancer, which was T-DM1. We saw updates this year not only for progression-free survival, but also for overall-survival. For progression-free survival, we’re now seeing a benefit of over 22 months for trastuzumab deruxtecan, compared to T-DM1, so that’s almost two years difference, which is really just amazing...
So we saw updates from DESTINY-Breast03 at San Antonio here in 2022. This trial had previously reported a significant improvement in progression-free survival with trastuzumab deruxtecan, compared to the previous second-line therapy for HER2-positive metastatic breast cancer, which was T-DM1. We saw updates this year not only for progression-free survival, but also for overall-survival. For progression-free survival, we’re now seeing a benefit of over 22 months for trastuzumab deruxtecan, compared to T-DM1, so that’s almost two years difference, which is really just amazing.
We’re also, although overall-survival medians have not been reached, overall-survival is statistically different, and so we’re seeing not only an improvement of progression-free survival by almost two years, but also an improvement in overall-survival. Considering quite a few patients kind of crossed over, or set another way, ended up getting trastuzumab deruxtecan after they went off study, if they received T-DM1 in countries where it was approved, the fact that we’re still seeing overall survival benefits is even more impressive.